



Supplement Figure S1. Production of rNfCB and its cytotoxicity to BV-2 microglial cells. (a) Purification of rNfCB. The recombinant protein was produced in *E. coli*, purified, and analyzed by 12% SDS–PAGE. Lane M, Size marker proteins, lane rNfCB, purified rNfCB. (b) Cytotoxicity assay. Different concentration of LPS-depleted rNfCB (0, 5, 10, 15, 20, 40, 50, 100, or 150 µg/ml) was treated to BV-2 microglial cells and incubated for 24 h. Cell viability was measured using CellTiter-Blue® Cell Viability Assay (Promega). Percentage of cell viability was calculated by comparing each value to negative control without treatment of rNfCB (100%). Values were presented as mean ± standard deviation of three independent assays.